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ABSTRACT  
Resting systolic blood pressure is lower in active hypoestrogenic women with functional 
hypothalamic amenorrhea.  Our prior observations in normotensive postmenopausal women 
stimulated the hypotheses that compared to eumenorrheic women, their reflex renin-angiotensin-
aldosterone system responses to an orthostatic challenge (graded lower body negative pressure) 
would be attenuated whereas to defend blood pressure reflex increases in muscle sympathetic 
nerve activity would be augmented.  To test these hypotheses, we assessed, in recreationally 
active women, 12 with amenorrhea (ExFHA; aged 25±1 years; body mass index 20.7±0.7 kg/m2; 
mean±SEM) and 17 with eumenorrhea (ExOv; 24±1 years; 20.9±0.5kg/m2), blood pressure, 
heart rate, plasma renin, angiotensin II, aldosterone and muscle sympathetic nerve activity burst 
incidence at supine rest and during graded lower body negative pressure (-10, -20, and -
40mmHg).  At baseline, heart rate and systolic blood pressure were lower (P<0.05) in ExFHA 
(47±2 beats/min and 94±2 mmHg) compared with ExOv (56±2 beats/min and 105±2 mmHg) 
women, but muscle sympathetic nerve activity and renin-angiotensin-aldosterone system 
constituents were similar (P>0.05).  In response to graded lower body negative pressure, heart 
rate increased (P<0.05) and systolic blood pressure decreased (P<0.05) in both groups, but these 
remained consistently lower in ExFHA  (P<0.05).  Lower body negative pressure elicited 
increases (P<0.05) in renin, angiotensin II and aldosterone in ExOv, but not ExFHA, women 
(P>0.05).  Muscle sympathetic nerve activity burst incidence increased reflexively in both 
groups, but moreso in ExFHA women (P<0.05).   Otherwise healthy hypoestrogenic ExFHA 
women demonstrate low blood pressure and disruption of the normal circulatory response to an 
orthostatic challenge: plasma renin, angiotensin II and aldosterone fail to increase and blood 
pressure is defended by an augmented sympathetic vasoconstrictor response. 
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INTRODUCTION 
Functional hypothalamic amenorrhea (FHA) is a reversible cause of ovarian suppression in 
premenopausal women 1. Its prevalence is markedly higher in recreationally and competitively 
exercising women and women with physically demanding jobs (~1-44%) than in sedentary 
women (~2-5%) 2, 3.  Hypothalamic-pituitary-ovarian suppression in physically active women 
with FHA (ExFHA) has been related causally to energy deficiency (i.e., caloric deficit) due to 
high energy expenditure and insufficient energy intake (i.e., low caloric intake) 4.   
Circulating estradiol concentrations in women with ExFHA are chronically low and 
resemble those observed in postmenopausal women and in men 5, 6.  However in contrast to 
postmenopausal women, who are more likely than men to develop hypertension with advancing 
age 7, ExFHA women have lower resting systolic BP and heart rate (HR) than age-matched 
estrogen-replete physically active women 8, 9.  The presence of low arterial BP despite 
hypoestrogenemia suggests that estrogen deficiency may have different consequences for BP 
regulation in premenopausal and postmenopausal women.  
The sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) 
are cornerstones of BP regulation.  Estrogen modulates both.  In estrogen deficient post-
menopausal women, efferent skeletal muscle sympathetic nerve activity (MSNA) is elevated and 
renin mass, plasma renin activity, angiotensin II and aldosterone fail to increase reflexively in 
response to simulated orthostatic stress 10, whereas exogenous estrogen increases circulating 
levels of angiotensinogen, angiotensin I, renin, and angiotensin II 10, 11  and decreases MSNA 12.   
The purpose of this study was to investigate, for the first time, the consequences of 
hypoestrogenemia in premenopausal women for BP regulation.  We compared, in ExFHA 
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women and estrogen- replete eumenorrheic women, MSNA burst incidence and plasma renin, 
angiotensin II and aldosterone concentrations both at rest and during an orthostatic hypotensive 
challenge (graded lower body negative pressure, LBNP) applied to stimulate reflexively 
sympathetic outflow and the RAAS.   We anticipated, from the literature8, 9, that women with 
ExFHA would have lower BP than eumenorrheic women BP both at rest and during 
LBNP.   Based on our prior findings in postmenopausal women 10, we hypothesized that their 
reflex RAAS response to this orthostatic challenge would be attenuated, whereas to defend BP 
their reflex increase in MSNA burst incidence would be augmented.   
 
METHODS 
Subjects: Volunteers were recruited by posters targeting currently physically active 
premenopausal women. Screening procedures included general questionnaires on exercise habit, 
eating behaviour, menstrual cycle, and medical health history. Eligibility criteria for the study 
included: 1) age 18 to 35 yrs; 2) good health determined by absence of chronic illnesses, 
including diabetes, hyperprolactinemia, poly-cystic ovarian syndrome, and thyroid disease; 3) 
stable menstrual status over the preceding 3 months defined as i) menstrual cycles between 25-35 
days for menstruating women, or ii) complete absence of menses for at least 90 consecutive days 
in amenorrheic women; 4) taking no medications; 5) non-smoker; 6) not currently dieting and 
weight stable for the preceding 3 months; 7) absence of hormonal therapy for at least 6 months; 
8) no history or current clinical diagnosis of eating disorders; 9) participating in purposeful 
exercise for >2hrs per week; and 10) no other contraindications that would preclude participation 
in the study. The study was approved by the local University and Hospital Research Ethics 
Boards.  All volunteers provided written informed consent. 
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Study Groups:  Two groups of physically active women were established: eumenorrheic 
ovulatory women (ExOv; n=17), and FHA women (ExFHA; n=12), defined as cessation of 
menses for 90 or more days 2.  Women reporting unpredictable menstrual cycles of variable 
length (i.e., oligomenorrhea) were excluded.  ‘Exercising’ status was defined as >2 hours/week 
of structured exercise for >6 months and a peak aerobic capacity of ≥40 ml/kg/min 8.  In 
eumenorrheic women, ovulatory status was confirmed in the menstrual cycle prior to testing by 
using a commercial urinary ovulation hormone kit (Clearblue Easy, Unipath Diagnostics, 
Waltham, MA).  
 
Subject Preparation: All measures were obtained during the early follicular phase (low estrogen 
and progesterone; days 2-6) of the menstrual cycle in eumenorrheic subjects, and on a random 
day (low estrogen and progesterone) for amenorrheic women.  Thus, we were able to compare 
the cardiovascular effects of cyclically low estrogen versus chronically low estrogen levels.  All 
tests occurred in the morning between 0930-1030 in a quiet ambient temperature room (22-24 
ºC). Volunteers had fasted at least 2 hours and abstained from alcohol 12 hours, and caffeine and 
exercise for 24 hours, prior to testing.    
 
Anthropometric Measures and Body Composition: Total body mass and height were determined 
using a physician’s balance scale (Detecto, Webb City, MO). Body composition was determined 
using dual-energy x-ray absorptiometry (DXA; Prodigy, General Electric Lunar Corporation, 
Madison, WI). Central fat mass was determined from the fat mass (kg) measured in the trunk, 
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and peripheral fat mass was determined as the sum of fat mass (kg) measured in the arms and 
legs. 
 
Peak Aerobic Capacity: On a separate study day, peak aerobic capacity (VO2 peak) was 
measured using a metabolic cart during a progressive treadmill test to exhaustion (Moxus 
Modular VO2 System, Applied Electrochemistry Inc., Pittsburgh, PA).   
 
Blood Sampling:  Blood samples were collected from a cannula placed in an antecubital vein at 
baseline and during the last minute of each stage of LBNP for determination of plasma renin and 
angiotensin II and serum aldosterone.  Baseline blood samples for non-RAAS constituents were 
collected successfully in all subjects either from an indwelling forearm venous cannula or using 
standard venipuncture.  Non-RAAS constituents included serum measures of 17 β-estradiol, 
progesterone, testosterone, follicle stimulating hormone, luteinizing hormone and sex hormone 
binding globulin (SHBG).  On a separate day, 8-hour fasted serum free triiodothyronine (T3) was 
also assessed to provide an estimate of energy status, with low T3 levels indicating low energy 
status (i.e., energy deficiency) 13.  Free androgen index ([total testosterone/SHBG]*100) was 
calculated to provide an estimate of androgenicity 14.  All assays were run by the Toronto 
General Hospital Core Laboratory.   
 
Blood Pressure and Heart Rate:  Systolic (SBP), diastolic (DBP), mean arterial BP (MAP) and 
HR were recorded from the left upper-arm using an automated device (Dinamap Pro 100, 
Critikon, USA).  Brachial BP and HR were assessed at one minute intervals at baseline (three 
consecutive stable measures) and every minute throughout each stage of LBNP.  The recordings 
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acquired during the last four minutes of each LBNP stage were averaged to acquire a mean value 
for each LBNP stage.  Continuous recordings of HR and BP were also acquired using lead II of 
an electrocardiogram and a photoplethysmographic device on the index finger (Portapres Model-
2, Finapres Medical Systems BV, USA), respectively.   
 
Muscle Sympathetic Nerve Activity: Multi-unit recordings of post-ganglionic MSNA were 
obtained with a unipolar tungsten electrode inserted selectively into a muscle-nerve fascicle of 
the right fibular (peroneal) nerve using previously described techniques 15. The nerve signals 
were amplified, filtered (bandwidth 700 to 2000 Hz), rectified, and integrated to obtain a mean 
voltage display of sympathetic nervous activity.  A recording of MSNA was considered 
acceptable when the following criteria were met: i) spontaneous bursts of neural discharge 
synchronous with the heart rate; ii) no response to arousal stimuli or skin stroking; iii) an 
increase in nerve burst frequency with apnoea; iv) a signal to noise ratio of 3:1 16. With the 
subject lying quietly, recordings were acquired at baseline and during each stage of LBNP.  
Signals were digitized (LabVIEW, National Instruments Corporation, Austin, TX, USA). 
Variables of interest included burst incidence (bursts/100 heart beats) and burst frequency 
(bursts/minute).  Because the purpose of this component of the protocol was to compare the 
reflex effects of a stimulus (unloading of mechanoreceptor nerve afferents by LBNP) on central 
sympathetic outflow between two groups known to differ with respect to cardiac frequency, the 
principal outcome variable was the heart rate-independent measure, MSNA burst incidence 
(bursts/100 cardiac cycles), which is derived from burst frequency (bursts/min) and heart rate.  
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LBNP:  With subjects supine, the lower body was encased in a custom built chamber sealed at 
the level of the iliac crest and attached to a vacuum source 10.  A trap door permitted lower leg 
access for microelectrode placement.  HR, BP, respiratory excursions and MSNA were recorded 
continuously at baseline and during each stage of LBNP.  MSNA was recorded in 8-minute 
stages at baseline and during sequential graded application of LBNP at -10mmHg, -20mmHg and 
-40mmHg.  Each LBNP stage was followed by 5-minutes of recovery (i.e., no LBNP).  LBNP 
was terminated if SBP fell <80mmHg, pallor was observed, and/or subjective feelings of nausea, 
dizziness and/or light-headedness were reported.   
 
Statistics:  All data sets were tested for non-normality, homogeneity of variance, and outliers. 
All data sets were normally distributed and no outliers were detected.  Group differences at 
baseline were detected using one-way analysis of variance (ANOVA).  Within- and between-
group analyses of responses to LBNP, including change (∆) in measures compared to baseline, 
were determined using repeated measures ANOVA.  When assumptions of sphericity were 
violated, the Greenhouse-Geisser correction was used.  Using separate data for each group, 
Pearson’s correlational analyses were used to determine significant linear independent 
associations between BP and neurohumoral variables of interest.  Data were analyzed using 
packaged software (SPSS version 20; SPSS Inc., Chicago, IL).  All data are presented as the 
mean ± SEM. A significance level of P<0.05 was used to detect the differences for statistical 
procedures.   
 
 
RESULTS 
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Subject Characteristics: The two study groups did not differ (P>0.05) in age, height, weight, 
body mass index, body composition, body fat distribution, cardio-respiratory fitness level, free 
androgen index, or serum measures of testosterone, progesterone and follicle stimulating 
hormone (Table 1).  In contrast, serum estrogen, free T3 and luteinizing hormone concentrations 
were significantly lower (P<0.05) in ExFHA women.   
 
Baseline Values:  Resting BP and HR values for the two study groups (n=29) differed between 
the groups.  Specifically, SBP, MAP and HR were lower (P<0.05) in ExFHA women compared 
with ExOv women (Figure 1).  DBP did not differ between the groups (P=0.25).  Acceptable 
microelectrode recordings of MSNA were obtained in 22 of the 29 women (ExOv, n=12; 
ExFHA, n=10).  Despite lower resting HR in ExFHA women, MSNA burst incidence (burst/100 
heart beats) did not differ (P>0.05) between groups (Table 2).  Differences in baseline MSNA 
burst frequency (bursts/minute) were also not detected (P>0.05).  Blood samples for RAAS 
components were successfully collected in 20 subjects (ExOv, n=11; ExFHA, n=9).  Of the 9 
subjects that were not tested for RAAS, cannulization was unsuccessful in 7 women and was 
refused by 2 women.  RAAS components, including the aldosterone/renin ratio, did not 
statistically differ (P>0.05) between the groups (Table 2).   
 
Responses to LBNP:  LBNP elicited similar (P>0.05) within-group decreases in SBP, MAP and 
DBP (P<0.001 for all measures), and increases (P<0.001) in HR (Figure 1).  Significant 
differences in between-group responses to graded LBNP were observed for SBP (P<0.01) and 
HR (P<0.01), with ExFHA demonstrating consistently lower values than ExOv women.  While 
between-group DBP values during LBNP did not differ (P=0.45), MAP trended (P=0.06) 
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toward lower values in ExFHA.  ∆HR, ∆SBP, ∆DBP and ∆MAP values during LBNP did not 
differ (P>0.05; all measures) between the groups.  LBNP did not elicit pre-syncopal symptoms 
in any subject. 
Within-groups, LBNP caused MSNA burst frequency (P<0.001) and burst incidence 
(P<0.001) to increase similarly (P>0.05) in both groups (Figure 1).  In contrast, between-groups, 
MSNA adjusted for HR (burst incidence; P=0.04), but not burst frequency (P>0.05), was 
significantly higher in ExFHA versus ExOv women at -20 and -40 mmHg.  ∆MSNA burst 
incidence, but not frequency, also demonstrated significantly greater (P<0.05) values in ExFHA 
versus ExOv women at -20 and -40 mmHg (Figure 1).   
Within groups, LBNP elicited significant increases in renin (P<0.01), and Ang II 
(P=0.01), but not aldosterone (P>0.05; Figure 1).  However, significant (P<0.05) between-group 
interactions in response to LBNP were observed for each RAAS component. Notably, in contrast 
to ExOv women, ExFHA women demonstrated no activation of either renin or Ang II during 
LBNP (Figure 1).  Although not significant (P>0.05), aldosterone appeared to be decreased in 
response to LBNP in ExFHA, yet increased in ExOv women.  The aldosterone/renin ratio (Table 
2) did not differ (P>0.05) between the groups.  Within- and between-group analyses using ∆ 
measures of each RAAS component did not alter the findings.   
 
Correlates:  Using separate data for each group, no significant correlates (p>0.05) were detected 
between MSNA, BP, and RAAS.  All other circulating hormones were also not related (p>0.05) 
to these variables. 
 
DISCUSSION  
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This, to our knowledge, is the first study to report hemodynamics, efferent sympathetic nerve 
discharge and plasma renin, angiotensin II and aldosterone concentrations both at rest and in 
response to their acute reflex activation by simulated orthostatic stress in young estrogen 
deficient physically active premenopausal with functional hypothalamic amenorrhea (ExFHA).  
This experiment yielded several novel findings.  Compared with body mass index-, body 
composition-, age- and fitness-matched eumenorrheic women, hypoestrogenic women with 
functional hypothalamic amenorrhea demonstrated: i) similar tonic basal efferent sympathetic 
outflow to the lower limb and similar plasma renin, angiotensin II and aldosterone 
concentrations, yet lower resting heart rate and systolic blood pressure; ii) no reflex activation of 
renin, angiotensin II, or aldosterone in response to LBNP; and iii) consistently lower blood 
pressure and heart rate during this orthostatic challenge despite greater reflex increases in muscle 
sympathetic burst incidence.   These findings are consistent with the concept that hypoestrogenic 
ExFHA women rely upon augmented sympathoneural vasoconstrictor responsiveness to 
maintain blood pressure when standing.  
Compared with eumenorrehic women, the BP and HR of ExFHA women were 
significantly lower and sympathetic burst incidence tended to be higher.  The absence of 
correlation between resting arterial BP and MSNA in either ExFHA or ExOv women is 
consistent with prior observations in men and in women less than 40 years old 17, 18.   In both 
groups of women, graded LBNP elicited the anticipated reflex increase in MSNA burst incidence 
19.  However, the finding that the magnitude of this response is greater in ExFHA than in ExOv 
women has not been previously reported.  Although the precise central mechanism responsible 
for greater reflex sympatho-excitation in hypoestrogenic women remains to be determined, 
human and animal studies have established that both endogenous and exogenous estrogen lower 
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resting sympathetic discharge 12, 20, 21.   Absence of estrogen-mediated sympatho-inhibition 
would be anticipated to increase MSNA burst incidence.  By contrast, information concerning 
the effects of endogenous and exogenous estrogen on reflex MSNA responses to orthostatic 
stress is both limited and inconsistent.   For example, head-up tilt has been reported to elicit both 
lower 22 and similar 23 MSNA responses in young women compared with men.  Simulated 
orthostatic stress augments MSNA more during the mid-luteal phase (high estrogen and 
progesterone) than in the early follicular phase (low estrogen and progesterone) of the menstrual 
cycle 24, 25.   Combined oral hormonal contraceptives in premenopausal women 26 and 
transdermal estrogen therapy in postmenopausal women 27 are reported not to influence the 
magnitude of MSNA increases elicited by orthostatic stress.  The reason for such conflicting 
findings has yet to be resolved but difference in the mode of orthostatic challenge, the 
comparison of endogenous versus exogenous estrogen preparations, and confounding effects of 
progesterone 21 are plausible candidates.   
It might be anticipated, from their lower BP both at rest and during LBNP, and from their 
augmented MSNA response that the plasma renin, angiotensin II, and aldosterone of ExFHA 
women would be significantly greater than those of their ExOv counterparts under both resting 
conditions and in response to this orthostatic challenge.  However, the opposite was observed.  
Unlike ExOv women, in whom renin and angiotensin II increased reflexively as expected in 
response to lowering of systolic BP with graded LBNP 10, 28, LBNP had no effect on the plasma 
renin, angiotensin II, or aldosterone of ExFHA women.    Although the causal mechanism 
responsible for the absent RAAS response in ExFHA women cannot be established with 
certainty, there is a large body of experimental evidence implicating estrogen deficiency.  RAAS 
responses to graded LBNP are similarly absent in healthy normotensive postmenopausal women 
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10 .  After 1 month of oral estradiol (2 mg daily), LBNP elicited reflex increases in plasma renin 
activity and angiotensin II corresponding to those observed in a comparator group of healthy 
premenopausal women studied under identical conditions 10.   Estrogen has been shown to up-
regulate angiotensinogen gene expression 29, increase plasma angiotensin I and II concentrations, 
reduce angiotensin converting enzyme activity, alter plasma renin concentrations 10, 11, and 
modulate local factors known to regulate renal renin secretion.  For example, in the immediate 
vicinity of the juxtaglomerular cells, renal endothelial nitric oxide stimulates and endothelin 
inhibits renin secretion 30.  Estrogen stimulates endothelial nitric oxide and inhibits endothelin 
production 31.   Thus, renal renin release may be diminished in estrogen deficient states.   
RAAS activity has also been associated positively with circulating thyroid hormone 
levels 32. Thus, it is plausible that low triiodothyronine, as observed in ExFHA women in the 
current and in previous 8, 9 studies, may also contribute to this low renin state.  Considering the 
similarity of body mass index in our two groups and the clinical absence of edema, intravascular 
volume expansion is an unlikely RAAS-suppressive mechanism. 
The authors acknowledge certain study limitations.  Hydration status can influence 
MSNA responses to orthostatic stress 23 while sodium depletion and protein overfeeding can  
increase RAAS activity 33.  Mild negative energy balance may contribute to 
hyperadiponectinemia, hypoleptinemia, and low triiodothyronine 34, 35.  These factors were not 
controlled for in the current study.  Because of our sample size, we may not have been able to 
detect associations between variables of interest that were in fact present.  Unknown is whether 
tissue RAAS or novel RAAS components, such as ang-(1-7) and the MAS receptor are altered in 
ExFHA women at rest or in response to an orthostatic challenge.  Finally, it is acknowledged that 
 Circulatory Regulation and Functional Amenorrhea 
15 
 
regional MSNA in the lower limb may differ from SNA directed to other organs such as the 
kidney and heart, and that cardiac vagal tone was not evaluated. 
In conclusion, circulatory regulation of hypoestrogenic but otherwise healthy ExFHA 
women differs from eumenorrheic women in several key respects.  BP and HR are lower at rest, 
and normal counter-regulatory responses to an orthostatic challenge are disrupted: plasma renin, 
angiotensin and aldosterone fail to increase and BP is defended by augmented reflex sympathetic 
vasoconstriction.  A body of experimental and clinical work supports the concept that these 
alterations are a consequence of relative estrogen deficiency.   
 
 
Perspectives 
The present study adds to a body of literature describing altered cardiovascular function in 
exercise trained women with functional hypothalamic amenorrhea, including impaired conduit 9, 
36 and resistance 8, 9 vessel function and increased regional vascular resistance 8, 9.  Similar 
hemodynamic changes have been documented in older sedentary hypoestrogenic 
postmenopausal women 37, 38.  We now report for the first time that compared with estrogen 
replete women, hypoestrogenic ExFHA women demonstrate: i) lower HR and BP during 
orthostatic stress as well as at rest; ii) a shift toward sympathetic control of BP regulation during 
LBNP; and iii) uncoupling of reflex sympathoneural and RAAS responses to this hypotensive 
stimulus.  These observations, likely a consequence of relative estrogen deficiency, are also 
strikingly similar to those identified previously in older postmenopausal women.  The long-term 
consequences of these neuro-humoral perturbations in youth are presently unknown, but it is now 
recognized that sympathetic activation contributes importantly to cardiovascular disease 
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development and progression 17, and it is of concern that studies in humans and non-human 
primates have identified estrogen deficiency due to FHA as a key contributing factor to 
premenopausal coronary artery disease 39, 40.  Conversely, since elevated circulating renin and 
plasma angiotensin II levels in population 41 and patient 42 studies, respectively, are associated 
with increased cardiovascular risk, mortality and morbidity, absence of RAAS activation by 
simulated orthostasis may confer an element of cardiovascular protection.  With growing 
numbers of young women participating in athletic activities 43, and a higher prevalence of 
hypothalamic estrogen deficiency in active than sedentary women 2,  longitudinal studies 
following such women through later premenopausal years and into menopause should be 
undertaken to ascertain the cardiovascular risk associated with such neurohumoral perturbations 
during early adulthood.     
  
Sources of Funding: PJH was funded by a Pfizer Cardiovascular Independent Research Award 
(NRA 3840028).   JSF holds the Canada Research Chair in Integrative Cardiovascular Biology.  
EOD received doctoral funding from the Canadian Institute of Health Research.  HM was 
supported by the Bluma Appel International Fellowship of Mount Sinai Hospital.  BLM was 
supported by an operating grant from the Heart and Stroke Foundation on Ontario. 
 
Conflicts of Interest: None 
 
 
 
 
 Circulatory Regulation and Functional Amenorrhea 
17 
 
 
REFERENCES   
 
1. Liu JH. Hypothalamic amenorrhea: Clinical perspectives, pathophysiology, and 
management. Am J Obstet Gynecol. 1990;163:1732-1736 
2. Otis CL, Drinkwater B, Johnson M, Loucks A, Wilmore J. American college of sports 
medicine position stand. The female athlete triad. Med Sci Sports Exerc. 1997;29:i-ix 
3. Friedl KE, Nuovo JA, Patience TH, Dettori JR. Factors associated with stress fracture in 
young army women: Indications for further research. Mil Med. 1992;157:334-338 
4. Williams NI, Helmreich DL, Parfitt DB, Caston-Balderrama A, Cameron JL. Evidence 
for a causal role of low energy availability in the induction of menstrual cycle 
disturbances during strenuous exercise training. J Clin Endocrinol Metab. 2001;86:5184-
5193 
5. O'Donnell E, Goodman JM, Harvey PJ. Cardiovascular consequences of ovarian 
disruption: A focus on functional hypothalamic amenorrhea in physically active women. 
J Clin Endocrinol Metab. 2011;96:3638-3648 
6. Carmina E, Stanczyk FK, Lobo RA. Laboratory assessment In: Strauss III JF, Barbieri 
RL, eds. Yen and jaffe's reproductive endocrinology:  Physiology, pathophysiology and 
clinical management Philidelphia, PA: Saunders; 2014:822-858. 
7. Reckelhoff JF. Sex steroids, cardiovascular disease, and hypertension: Unanswered 
questions and some speculations. Hypertension. 2005;45:170-174 
8. O'Donnell E, Harvey PJ, Goodman JM, De Souza MJ. Long-term estrogen deficiency 
lowers regional blood flow, resting systolic blood pressure, and heart rate in exercising 
premenopausal women. Am J Physiol Endocrinol Metab. 2007;292:E1401-1409 
 Circulatory Regulation and Functional Amenorrhea 
18 
 
9. O'Donnell E, Goodman JM, Mak S, Harvey PJ. Impaired vascular function in physically 
active premenopausal women with functional hypothalamic amenorrhea is associated 
with low shear stress and increased vascular tone. J Clin Endocrinol Metab. 
2014;99:1798-1806 
10. Harvey PJ, Morris BL, Miller JA, Floras JS. Estradiol induces discordant angiotensin and 
blood pressure responses to orthostasis in healthy postmenopausal women. Hypertension. 
2005;45:399-405 
11. Ichikawa J, Sumino H, Ichikawa S, Ozaki M. Different effects of transdermal and oral 
hormone replacement therapy on the renin-angiotensin system, plasma bradykinin level, 
and blood pressure of normotensive postmenopausal women. Am J Hypertens. 
2006;19:744-749 
12. Vongpatanasin W, Tuncel M, Mansour Y, Arbique D, Victor RG. Transdermal estrogen 
replacement therapy decreases sympathetic activity in postmenopausal women. 
Circulation. 2001;103:2903-2908 
13. Loucks AB, Heath EM. Induction of low-t3 syndrome in exercising women occurs at a 
threshold of energy availability. Am J Physiol. 1994;266:R817-823 
14. Rickenlund A, Carlstrom K, Ekblom B, Brismar TB, von Schoultz B, Hirschberg AL. 
Hyperandrogenicity is an alternative mechanism underlying oligomenorrhea or 
amenorrhea in female athletes and may improve physical performance. Fertil Steril. 
2003;79:947-955 
15. Wallin BG, Delius W, Hagbarth KE. Comparison of sympathetic nerve activity in 
normotensive and hypertensive subjects. Circ Res. 1973;33:9-21 
 Circulatory Regulation and Functional Amenorrhea 
19 
 
16. Notarius CF, Ando S, Rongen GA, Floras JS. Resting muscle sympathetic nerve activity 
and peak oxygen uptake in heart failure and normal subjects. Eur Heart J. 1999;20:880-
887 
17. Narkiewicz K, Phillips BG, Kato M, Hering D, Bieniaszewski L, Somers VK. Gender-
selective interaction between aging, blood pressure, and sympathetic nerve activity. 
Hypertension. 2005;45:522-525 
18. Ng AV, Callister R, Johnson DG, Seals DR. Age and gender influence muscle 
sympathetic nerve activity at rest in healthy humans. Hypertension. 1993;21:498-503 
19. Sundlof G, Wallin BG. Human muscle nerve sympathetic activity at rest. Relationship to 
blood pressure and age. J Physiol. 1978;274:621-637 
20. Saleh MC, Connell BJ, Saleh TM. Autonomic and cardiovascular reflex responses to 
central estrogen injection in ovariectomized female rats. Brain Res. 2000;879:105-114 
21. Minson CT, Halliwill JR, Young TM, Joyner MJ. Influence of the menstrual cycle on 
sympathetic activity, baroreflex sensitivity, and vascular transduction in young women. 
Circulation. 2000;101:862-868 
22. Shoemaker JK, Hogeman CS, Khan M, Kimmerly DS, Sinoway LI. Gender affects 
sympathetic and hemodynamic response to postural stress. Am J Physiol Heart Circ 
Physiol. 2001;281:H2028-2035 
23. Fu Q, Witkowski S, Okazaki K, Levine BD. Effects of gender and hypovolemia on 
sympathetic neural responses to orthostatic stress. Am J Physiol Regul Integr Comp 
Physiol. 2005;289:R109-116 
 Circulatory Regulation and Functional Amenorrhea 
20 
 
24. Carter JR, Lawrence JE, Klein JC. Menstrual cycle alters sympathetic neural responses to 
orthostatic stress in young, eumenorrheic women. Am J Physiol Endocrinol Metab. 
2009;297:E85-91 
25. Fu Q, Okazaki K, Shibata S, Shook RP, VanGunday TB, Galbreath MM, Reelick MF, 
Levine BD. Menstrual cycle effects on sympathetic neural responses to upright tilt. J 
Physiol. 2009;587:2019-2031 
26. Carter JR, Klein JC, Schwartz CE. Effects of oral contraceptives on sympathetic nerve 
activity during orthostatic stress in young, healthy women. Am J Physiol Regul Integr 
Comp Physiol. 2010;298:R9-R14 
27. Fadel PJ, Wang Z, Watanabe H, Arbique D, Vongpatanasin W, Thomas GD. Augmented 
sympathetic vasoconstriction in exercising forearms of postmenopausal women is 
reversed by oestrogen therapy. J Physiol. 2004;561:893-901 
28. Hinghofer-Szalkay HG, Vigas M, Sauseng-Fellegger G, Konig EM, Lichardus B, Jezova 
D. Head-up tilt and lower body suction: Comparison of hormone responses in healthy 
men. Physiol Res. 1996;45:369-378 
29. Hilliard LM, Sampson AK, Brown RD, Denton KM. The "his and hers" of the renin-
angiotensin system. Current hypertension reports. 2013;15:71-79 
30. Wagner C, Jensen BL, Kramer BK, Kurtz A. Control of the renal renin system by local 
factors. Kidney Int Suppl. 1998;67:S78-83 
31. Best PJ, Berger PB, Miller VM, Lerman A. The effect of estrogen replacement therapy 
on plasma nitric oxide and endothelin-1 levels in postmenopausal women. Annals of 
internal medicine. 1998;128:285-288 
 Circulatory Regulation and Functional Amenorrhea 
21 
 
32. Vargas F, Rodriguez-Gomez I, Vargas-Tendero P, Jimenez E, Montiel M. The renin-
angiotensin system in thyroid disorders and its role in cardiovascular and renal 
manifestations. J Endocrinol. 2012;213:25-36 
33. Swainson CP, Walker RJ. Renal haemodynamic and hormonal responses to a mixed 
high-protein meal in normal men. Nephrol Dial Transplant. 1989;4:683-690 
34. O'Donnell E, De Souza MJ. Increased serum adiponectin concentrations in amenorrheic 
physically active women are associated with impaired bone health but not with estrogen 
exposure. Bone. 2010;48:760-767 
35. O'Donnell E, Harvey PJ, De Souza MJ. Relationships between vascular resistance and 
energy deficiency, nutritional status and oxidative stress in oestrogen deficient physically 
active women. Clin Endocrinol (Oxf). 2009;70:294-302 
36. Zeni Hoch A, Dempsey RL, Carrera GF, Wilson CR, Chen EH, Barnabei VM, Sandford 
PR, Ryan TA, Gutterman DD. Is there an association between athletic amenorrhea and 
endothelial cell dysfunction? Med Sci Sports Exerc. 2003;35:377-383 
37. Lieberman EH, Gerhard MD, Uehata A, Walsh BW, Selwyn AP, Ganz P, Yeung AC, 
Creager MA. Estrogen improves endothelium-dependent, flow-mediated vasodilation in 
postmenopausal women. Ann Intern Med. 1994;121:936-941 
38. Moreau KL, Donato AJ, Tanaka H, Jones PP, Gates PE, Seals DR. Basal leg blood flow 
in healthy women is related to age and hormone replacement therapy status. J Physiol. 
2003;547:309-316 
39. Bairey Merz CN, Johnson BD, Sharaf BL, Bittner V, Berga SL, Braunstein GD, Hodgson 
TK, Matthews KA, Pepine CJ, Reis SE, Reichek N, Rogers WJ, Pohost GM, Kelsey SF, 
Sopko G. Hypoestrogenemia of hypothalamic origin and coronary artery disease in 
 Circulatory Regulation and Functional Amenorrhea 
22 
 
premenopausal women: A report from the nhlbi-sponsored wise study. J Am Coll 
Cardiol. 2003;41:413-419 
40. Kaplan JR, Manuck SB. Ovarian dysfunction, stress, and disease: A primate continuum. 
ILAR J. 2004;45:89-115 
41. de Boer RA, Schroten NF, Bakker SJ, Mahmud H, Szymanski MK, van der Harst P, 
Gansevoort RT, van Veldhuisen DJ, van Gilst WH, Hillege HL. Plasma renin and 
outcome in the community: Data from prevend. Eur Heart J. 2012;33:2351-2359 
42. Roig E, Perez-Villa F, Morales M, Jimenez W, Orus J, Heras M, Sanz G. Clinical 
implications of increased plasma angiotensin ii despite ace inhibitor therapy in patients 
with congestive heart failure. Eur Heart J. 2000;21:53-57 
43. Javed A, Tebben PJ, Fischer PR, Lteif AN. Female athlete triad and its components: 
Toward improved screening and management. Mayo Clin Proc. 2013;88:996-1009 
 
  
 Circulatory Regulation and Functional Amenorrhea 
23 
 
Novelty and Significance  
What is new?  
This is the first study to examine the effects of premenopausal estrogen deficiency on 
mechanisms of blood pressure regulation. 
 
We report for the first time that compared with their estrogen replete counterpart, estrogen 
deficient physically active premenopausal women with functional hypothalamic amenorrhea 
(FHA) demonstrate augmented muscle sympathetic nerve activity (MSNA) yet absence of renin-
angiotensin-aldosterone system (RAAS) activation during orthostatic stress. 
 
What is relevant?  
The cardiovascular effects of estrogen deficiency per se in postmenopausal women are unclear, 
in part due to the confounding effects of aging and oftentimes presence of co-morbidities.  
Otherwise healthy physically active premenopausal women with FHA (ExFHA) provide a 
unique model with which to examine the cardiovascular effects of estrogen deficiency. To date, 
the current study is the first to use this model of estrogen deficiency to examine the effects of 
hypoestrogenemia on blood pressure regulation. 
 
Summary 
The present study demonstrates a shift toward greater sympathetic and a withdrawal of RAAS 
support of arterial BP in ExFHA women during hypotensive stimuli.  These results indicate 
altered neurohumoral control of blood pressure in ExFHA women, suggesting an important role 
for endogenous estrogen in blood pressure regulation in premenopausal women. 
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Key words: blood pressure, estrogens, exercise, renin-angiotensin system, sympathetic nervous 
system  
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Figure 1:  Graphs showing the effects of lower body negative pressure in exercising 
eumenorrheic women (ExOv;  closed circles) and amenorrheic women (ExFHA; open circles) on 
cardiovascular measures, including: hemodynamic measures of systolic blood pressure (A), 
mean arterial blood pressure (B), heart rate (C); serum measures of renin (D), angiotensin II (E), 
and aldosterone (F); and muscle sympathetic nerve activity, assessed as burst frequency 
(bursts/min) (G), burst incidence (bursts/100 heart beats) (H), and change in burst incidence from 
baseline (I).  * P<0.05 between-groups for the given condition.  Repeated measures analysis of 
variance for effects of LBNP, GROUP, and interactions between these factors (LBNP x 
GROUP) are reported separately on each graph.  Values are mean±SEM. 
 
Table 1.  Baseline subject characteristics. 
 
  ExOv ExFHA P  
  (n=17) (n=12)   
Age (yrs) 24±1 25±1 0.308 
Height (cm) 166±2 168±1 0.316 
Weight (kg) 57.5±1.9 58.4±2.1 0.761 
BMI (kg/m2) 20.9±0.5 20.7±0.7 0.828 
Body fat (%) 23.5±1.8 21.8±2.1 0.592 
Lean mass (kg) 41.9±1.6 44.2±1.7 0.377 
VO2 peak (ml/kg/min) 47.1±1.3 46.3±1.9 0.666 
Estradiol (pmol/L) 154±24 87±13 0.045 
Progesterone (nmol/L) 1.6±0.2 1.4±0.2 0.634 
Free T3 (pmol/L) 4.2±0.2 3.6±0.1 0.017 
Testosterone (nmol/L) 2.1±0.1 2.4±0.3 0.246 
SHBG (nmol/L) 51±3 51±4 0.982 
FAI (au) 4.6±0.3 4.8±0.7 0.762 
LH (IU/L) 4.1±0.9 1.6±0.4 0.013 
FSH (IU/L) 7.6±2.4 5.4±0.8 0.318 
Amenorrhea (days)†  - 1061±319 - 
Values mean±SEM. 
 
BMI, body mass index; FAI, free androgen index; FSH, follicle stimulating hormone; 
LH, leutinizing hormone; SHBG, sex hormone binding globulin; T3, triiodothyronine; 
VO2 peak, peak oxygen uptake. 
 
† Range 150-3132 days. 
Table 2.  Hemodynamic responses of the groups at baseline and during graded LBNP (mmHg). 
  Ba -10 -20 -40 
          
SBP (mmHg) 
         ExOv 105±2 101±2* 100±2* 98±1* 
     ExFHA 94±2† 93±2† 92±2† 90±3†* 
DBP (mmHg) 
         ExOv 60±1 56±2* 54±2* 53±2* 
     ExFHA 58±6 56±2 53±2* 51±2* 
MAP (mmHg) 
         ExOv 75±1 71±2* 69±2* 68±2* 
     ExFHA 70±2† 68±2 66±2* 64±2* 
PP (mmHg) 
         ExOv 45±2 45±2 45±2 45±2 
     ExFHA 36±2† 36±2† 39±2† 39±2† 
HR (b/min) 
         ExOv 56±2 58±2 62±3* 72±4* 
     ExFHA 47±2† 48±2† 49±2† 60±2†* 
Values are mean±SEM. 
 
Ba, baseline; DBP, diastolic blood pressure; HR, heart rate; MAP, mean arterial pressure; PP, 
pulse pressure; SBP, systolic blood pressure. 
 
* Significantly different from baseline within-groups, p<0.05. 
† Significantly different between-groups for given LBNP, p<0.05. 
 
 
Table 3. Neurohumoral measures at baseline and during graded LBNP (mmHg). 
  Ba -10 -20 -40 
          
Renin (pmol/L)* 
         ExOv 8.0±2.0 7.4±1.8 8.7±2.0 12.5±2.5† 
     ExFHA 4.0±0.8 4.2±0.8 4.3±0.7‡ 4.8±0.9‡ 
Ang II (pmol/L)* 
         ExOv 3.9±0.8 4.1±0.9 5.3±1.4† 8.6±1.9† 
     ExFHA 2.3±0.3 2.6±0.4 2.1±0.3‡ 2.0±0.4‡ 
Aldo (pmol/L)* 
         ExOv 88±16 74±8 77±9 134±30 
     ExFHA 132±32 117±32 104±25 96±27 
MSNA (frequency) §  
         ExOv 8±2 10±2 13±2† 22±3† 
     ExFHA 10±2 13±3 18±2† 27±2† 
MSNA (incidence) § 
         ExOv 15±3 18±4 22±4† 33±4† 
     ExFHA 22±5 28±6 37±4‡,† 45±4‡,† 
Values are mean±SEM. 
 
Ba, baseline; aldo, aldosterone; ang II, angiotensin II; frequency, burst frequency measuring 
number of bursts per minute; incidence, burst incidence measuring number of bursts per 100 
heart beats; MSNA, muscle sympathetic nerve activity. 
 
* ExOv n=11; ExFHA n=10 
† Significantly different from baseline within-groups, p<0.05 
‡ Significantly different between-groups for given LBNP, p<0.05 
§ ExOv, n=12; ExFHA, n=10 
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